After Teva Pharmaceutical International reported fourth-quarter and full-year 2016 on Monday, only a few analysts weighed in initially, but the consensus is slowly growing more negative.
Shares of Sage Therapeutics saw a handy gain on Monday after the company announced a successful mid-stage trial for the treatment of major depressive disorder.
Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss.
Gilead Sciences Inc. (NASDAQ: GILD) reported its fourth-quarter earnings after the markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the consensus estimates…
Teva Pharmaceutical saw its shares tumble on Tuesday after the company announced a changing of the guard. This CEO departure may have been long overdue.